Compare Natco Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CIPLA NATCO PHARMA/
CIPLA
 
P/E (TTM) x 15.6 23.3 67.1% View Chart
P/BV x 3.1 2.4 129.0% View Chart
Dividend Yield % 1.5 0.7 214.7%  

Financials

 NATCO PHARMA   CIPLA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
CIPLA
Mar-19
NATCO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,080678 159.3%   
Low Rs671484 138.8%   
Sales per share (Unadj.) Rs592.1198.2 298.7%  
Earnings per share (Unadj.) Rs188.418.5 1,017.1%  
Cash flow per share (Unadj.) Rs206.335.0 589.8%  
Dividends per share (Unadj.) Rs8.253.00 275.0%  
Dividend yield (eoy) %0.90.5 182.4%  
Book value per share (Unadj.) Rs833.6186.3 447.4%  
Shares outstanding (eoy) m36.90805.70 4.6%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x1.52.9 50.5%   
Avg P/E ratio x4.631.4 14.8%  
P/CF ratio (eoy) x4.216.6 25.6%  
Price / Book Value ratio x1.13.1 33.7%  
Dividend payout %4.416.2 27.0%   
Avg Mkt Cap Rs m32,311468,031 6.9%   
No. of employees `0004.822.6 21.3%   
Total wages/salary Rs m3,25628,565 11.4%   
Avg. sales/employee Rs Th4,522.57,053.1 64.1%   
Avg. wages/employee Rs Th674.01,261.5 53.4%   
Avg. net profit/employee Rs Th1,439.0659.1 218.3%   
INCOME DATA
Net Sales Rs m21,848159,710 13.7%  
Other income Rs m4044,766 8.5%   
Total revenues Rs m22,252164,475 13.5%   
Gross profit Rs m9,28430,973 30.0%  
Depreciation Rs m66213,263 5.0%   
Interest Rs m1541,684 9.1%   
Profit before tax Rs m8,87220,791 42.7%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9205,695 33.7%   
Profit after tax Rs m6,95214,924 46.6%  
Gross profit margin %42.519.4 219.1%  
Effective tax rate %21.627.4 79.0%   
Net profit margin %31.89.3 340.5%  
BALANCE SHEET DATA
Current assets Rs m21,307124,266 17.1%   
Current liabilities Rs m5,92037,715 15.7%   
Net working cap to sales %70.454.2 130.0%  
Current ratio x3.63.3 109.2%  
Inventory Days Days7391 80.8%  
Debtors Days Days10795 112.3%  
Net fixed assets Rs m14,986105,190 14.2%   
Share capital Rs m3691,611 22.9%   
"Free" reserves Rs m30,353148,511 20.4%   
Net worth Rs m30,760150,123 20.5%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m37,151239,633 15.5%  
Interest coverage x58.613.3 439.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 88.2%   
Return on assets %19.16.9 276.0%  
Return on equity %22.69.9 227.3%  
Return on capital %29.311.8 247.9%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32257,410 18.0%   
Fx outflow Rs m2,97819,041 15.6%   
Net fx Rs m7,34338,368 19.1%   
CASH FLOW
From Operations Rs m4,63616,911 27.4%  
From Investments Rs m-11,155-16,687 66.8%  
From Financial Activity Rs m6,509-3,487 -186.7%  
Net Cashflow Rs m-18-3,451 0.5%  

Share Holding

Indian Promoters % 52.0 16.0 325.3%  
Foreign collaborators % 1.5 20.8 7.1%  
Indian inst/Mut Fund % 7.8 12.2 64.3%  
FIIs % 16.6 23.7 70.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.0 26.2 99.2%  
Shareholders   25,395 161,166 15.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  FDC LTD.  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)

Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 16, 2019 02:41 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS